CoChat

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jpd-191648

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Proposed flow chart to apply DAT imaging as an enrichment biomarker in clinical trials targeting subjects with motor signs of early PD. Each of the four inclusion criteria / steps must be met for subjects to be successfully enrolled into the PD clinical trial. The clinical criteria must be met before subjects undergo DAT SPECT imaging (final step).
Fig.1 Proposed flow chart to apply DAT imaging as an enrichment biomarker in clinical trials targeting subjects with motor signs of early PD. Each of the four inclusion criteria / steps must be met for subjects to be successfully enrolled into the PD clinical trial. The clinical criteria must be met before subjects undergo DAT SPECT imaging (final step).CC BY-NC · PubMed Central
Fig.2 The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies: [38, 39, 41, 59– 61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD: Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.
Fig.2 The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies: [38, 39, 41, 59– 61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD: Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 2

  1. Marek K, 2003, Adv Neurol, 91, 183
  2. Abi-Dargham A, 1996, J Nucl Med, 37, 1129

Cited by

See all 46

Metadata

Authors
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., Gallagher, J., Roach, A., Basseches, P., Grosset, D., Marek, K., & on behalf of the Critical Path for Parkinson’s Consortium
Affiliations
  • Critical Path Institute (US)
  • University College London, UK
  • Biogen (United States) (US)
  • European Medicines Agency (NL)
  • Parkinson's UK (GB)
  • Institute for Neurodegenerative Disorders (US)
  • Denali Therapeutics (United States) (US)
  • Pfizer (United States) (US)
  • Archer Daniels Midland (United States) (US)
  • National Center for Toxicological Research (US)
  • UCB, Brussels, Belgium
  • CPP Scientific Advisor, PA, USA
  • Rush University (US)
  • GE Healthcare, London, UK
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University of Glasgow (GB)
Corresponding author
Stephenson, Diane
Venue
Journal of Parkinson’s Disease
Published
2019-07-08
Volume
9
Issue
3
Pages
553-563
ISSN
  • 1877-7171 (ISSN-L)
  • 1877-718X
OpenAlex
W2958884967
Cited by
46
References
57
Citations by year
2026: 3 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 1
FWCI
4.57
Type
journal article
Language
en
Open access
Locations
  • Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Parkinson's Disease Foundation
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Biogen
  • Teva Pharmaceutical Industries
  • Davis Phinney Foundation
  • Strong
  • Parkinson's UK
  • University of Oxford
  • Newcastle University
  • University of Glasgow
  • Radboud Universiteit
  • H. Lundbeck A/S
  • U.S. Food and Drug Administration (U18FD005320)
  • Merck Sharp and Dohme
  • National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, dopamine transporter SPECT, patient selection, European Medicines Agency, Parkinson's Progression Markers Initiative, dopaminergic deficit, trial enrichment, statistical power
MeSH terms
Clinical Studies as Topic, Clinical Trials as Topic, Corpus Striatum, Humans, Parkinson Disease, Societies, Medical, Biomarkers, Tomography, Emission-Computed, Single-Photon, Dopamine Plasma Membrane Transport Proteins, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. https://app.cochat.ai/papers/10.3233/jpd-191648
The paper
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., . . . on behalf of the Critical Path for Parkinson’s Consortium. (2019). The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-191648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.